SMALL CELL LUNG CANCER

This study tests a combination of two drugs (adebrelimab and oral etoposide) in 47 elderly or frail patients with advanced small cell lung cancer. The goal is to see if the treatment can slow cancer growth and control the disease. Participants must be 65 or older, or have poor ph…

This study looks at how safe and effective a drug called adebrelimab is when combined with other treatments for people with advanced solid tumors, including lung and gastrointestinal cancers. About 300 participants will be observed in real-world settings to track side effects and…

This study tests a new drug called DXC006 combined with either immunotherapy or chemotherapy in about 200 people with small cell lung cancer. The goal is to find the safest dose and see if the combination can shrink tumors or slow the disease. Participants must be 18-75 years old…

This study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or one of three usual drugs (topotecan, lurbinectedin, or amrubicin) to see which works better and…

This study tests an experimental drug called FHD-286 in people with a specific type of small-cell lung cancer that has a marker called POU2F3. Participants must have already tried at least one standard chemotherapy. The drug is taken daily in 3-week cycles, and researchers will m…

This study tests a combination of the targeted drug limertinib plus chemotherapy (carboplatin and etoposide) in people with a specific type of lung cancer (EGFR-mutant NSCLC) that has transformed into small cell lung cancer after initial targeted therapy stopped working. About 30…

This study tests a maintenance therapy for people with extensive small cell lung cancer that has responded to initial treatment. The combination includes a liposomal form of irinotecan, platinum chemotherapy, an immune checkpoint inhibitor, and anlotinib. The goal is to see if th…

This study is testing a new drug called SYS6090, given together with chemotherapy or other targeted drugs, for people with advanced lung cancer that cannot be removed by surgery. The goal is to find safe doses and see if the combination can shrink tumors. About 596 adults aged 18…

This early-phase study tests whether adding the experimental drug DSP-0390 to the immunotherapy atezolizumab can safely help keep extensive stage small cell lung cancer under control after initial chemotherapy and immunotherapy. About 20 adults whose cancer did not worsen during …

This study tests a combination of a chemotherapy drug (nab-paclitaxel) and local radiation therapy for people with advanced small-cell lung cancer whose disease got worse after initial treatment. The goal is to see if this approach can control the cancer longer and with fewer sid…

This study tests a combination of two drugs, HLX43 and Serplulimab, in people with advanced lung cancer that has spread or cannot be removed by surgery. The goal is to find the right dose and see if the treatment shrinks tumors and is safe. About 120 adults aged 18 to 75 with non…

This study tests a drug called tarlatamab in 35 adults with small cell lung cancer that has spread to the brain but is not causing symptoms. Participants must have already received standard chemotherapy. The main goal is to see if the drug can shrink or eliminate brain tumors, as…

This study collects blood and tissue samples from 110 adults with advanced lung, head/neck, or mesothelioma cancer who are starting their first treatment. The samples will be stored in a biobank to help researchers study genetic changes and find better ways to predict treatment o…

This study will collect blood samples from 25 people with small cell lung cancer who are being treated with the drug tarlatamab. Researchers will analyze the samples to learn more about how the drug works, who might benefit most, and how to predict side effects like cytokine rele…

This study observes how patients with extensive-stage small cell lung cancer are treated in everyday hospital settings and how they respond. Researchers will collect data from medical records and follow participants for about 3 months at a time. The goal is to learn which treatme…